The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- The Problem With Being Too Cautious in Vaccine Trialson August 6, 2022 at 6:20 am
Scientists try to protect children and pregnant women from harm, but exclusion from early research carries a cost.
- Fauci and other health ‘experts’ are messing up monkeypox just as they did COVID, Ebola and AIDSon August 4, 2022 at 4:02 pm
We’d like to live in a world where we can trust the experts, both to know what to do and to promote policies that will help us. But we don’t live in that world.
- Marburg Virus Outbreak: 10 facts about the Ebola-like viruson August 1, 2022 at 10:40 pm
Ghana is racing against time to contain the outbreak of one of the highly lethal viruses in human history. Two people in the southern part of Ghana tested positive for the Marburg virus. The ...
- Promising Marburg vaccine yet to be tested on humans due to lack of fundingon July 26, 2022 at 11:34 pm
Oxford University’s Professor Teresa Lambe, the designer of the vaccine, fears Marburg disease is ‘now being seen in places where it’s never been seen before’ ...
- Ghana declares 1st ever outbreak of Ebola-like Marburg virus diseaseon July 18, 2022 at 11:30 pm
Marburg is almost as deadly as Ebola, but there are no treatments or vaccines. LONDON -- Ghana on Sunday declared its first ever outbreak of the Ebola-like Marburg virus disease. Blood samples ...
- Outbreak warning: Case of deadly EBOLA-LIKE virus with no treatment or vaccine reportedon July 18, 2022 at 2:26 pm
You can unsubscribe at any time. More info The Marburg virus is similar to Ebola, the haemorrhagic fever that left more than 10,000 people dead in the mid-2010s and spread around the world via air ...
- The role of the CDC in the management of COVID-19 vaccination programson July 15, 2022 at 12:35 am
These programs faced similar challenges as the COVID-19 vaccination programs, including lack of production and supply and inequitable distribution and access to the vaccines. Since the Ebola ...
- Potential Analysis Of Ebola Drug And Vaccines Market Analysis Insights By Latest Trends, Future Growth And Demandon July 13, 2022 at 4:44 am
Potential Analysis of Ebola drug and Vaccines Market - Global Opportunity Analysis and Industry Forecast to 2020 PORTLAND, OREGON, UNITED STATES, July 13, 2022 /EINPresswire.com / -- Potential ...
- Conference Report - I. Investigating New Vaccines: Ebola and HIVon July 12, 2022 at 5:00 pm
In our efforts to protect ourselves from diseases caused by viruses, we are constantly faced by the challenges posed by a nature that is steadily changing and adapting. These challenges can take ...
- Ebola Virus Vaccine market - Global Industry analysis, size, share, Growth, Trends, and Forecast 2022 To 2028.on July 12, 2022 at 7:02 am
According to our latest study, the "Ebola Virus Vaccine market size" was USD billions in 2022, which is expected to reach USD billions in 2028, growing at a CAGR rate over the analysis period.
via Google News and Bing News